Three of the pioneers in the use of CRISPR-Cas9 were Emmanuelle Charpentier, Jennifer Doudna and Feng Zhang. Doudna and Zhang helped start Editas Medicine 2013, but Doudna left the following year and joined Intellia Therapeutics.
Intellia Therapeutics currently has a value of over $ 700 million. Editas is worth over $ 1.3 billion. As chief researcher and aware of CRISPR, Jennifer Doudna clearly has a significant amount of shares in Editas and Intellia.
Incredibly Doudna released a statement condemning the controversial redeployment of human embryos.
It is important that these news does not impair the many important clinical efforts to use CRISPR technology to treat and cure disease in adults and children. Public and transparent discussion about the many uses of throughput technology must continue, which will take place in the next three days at the Hong Kong Human Resource Summit.
Human embryo redevelopment is highly controversial. Large shareholders in CRISPR companies hate all controversial uses of CRISPR that could trigger some backlash against CRISPR’s operations.